{"id":749209,"date":"2025-06-25T17:48:01","date_gmt":"2025-06-25T17:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=749209"},"modified":"2025-06-25T17:48:01","modified_gmt":"2025-06-25T17:48:01","slug":"krabbe-disease-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-alamab-therapeutics-zentalis-pharmaceuticals-isofol-medical-merck-eisai","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/krabbe-disease-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-alamab-therapeutics-zentalis-pharmaceuticals-isofol-medical-merck-eisai_749209.html","title":{"rendered":"Krabbe Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai"},"content":{"rendered":"
\n
\"Krabbe<\/a><\/div>\n
\n
Krabbe Disease Pipeline Insights<\/div>\n<\/div>\n<\/div>\n
Krabbe Disease companies are Jiangsu Hengrui Medicine, AstraZeneca, Y-mAbs Therapeutics, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., MacroGenics, Shanghai Pharmaceuticals Holding, Celgene, Hutchmed, MedImmune LLC, Lee’s Pharmaceutical Limited, EMD Serono, Iovance Biotherapeutics, Inc., BioEclipse Therapeutics, BioAtla, Inc., Celgene, Actuate Therapeutics Inc., and others.<\/div>\n

According to DelveInsight, the Krabbe Disease pipeline includes over eight leading companies actively engaged in developing more than eight treatment therapies for the condition.<\/p>\n

Krabbe Disease Overview:<\/strong><\/p>\n

Krabbe disease includes a spectrum of disorders, ranging from infantile-onset—marked by severe symptoms like extreme irritability, muscle stiffness (spasticity), and developmental delays appearing before 12 months of age—to later-onset forms, which can emerge anytime after the first year of life, even into the seventh decade. Traditionally, enzyme activity testing has shown that 85%–90% of symptomatic cases are infantile-onset, with only 10%–15% being later-onset. However, findings from newborn screening (NBS) suggest that later-onset cases may be more common than previously thought. Infantile-onset typically starts with normal development, followed by rapid neurological deterioration, and an average life expectancy of about 24 months (with a range from 8 months to 9 years). Later-onset forms of the disease are more variable in both symptoms and disease progression.<\/p>\n

Request for a detailed insights report on Krabbe Disease pipeline insights<\/a><\/strong><\/p>\n

“Krabbe Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Krabbe Disease Therapeutics Market.<\/p>\n

Key Takeaways from the Krabbe Disease Pipeline Report<\/strong><\/p>\n